Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
146 hedge funds and large institutions have $2.31B invested in Ra Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 71 funds opening new positions, 29 increasing their positions, 36 reducing their positions, and 44 closing their positions.
102% more capital invested
Capital invested by funds: $1.14B → $2.31B (+$1.16B)
61% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 44
23% more funds holding
Funds holding: 119 → 146 (+27)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
19% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 36
80% less call options, than puts
Call options by funds: $4.4M | Put options by funds: $22.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$93.5M |
| 2 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$84.3M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$81.3M |
| 4 |
Citigroup
New York
|
+$74.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$52.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$179M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$51.8M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$49.9M |
| 4 |
First Manhattan
New York
|
-$32.5M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$31.5M |
RARX Hedge Fund Activity: Q4 2019 in Review
146 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q4 2019, worth a combined $2.31B — up 102% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new RARX positions and 44 closed out — a net gain of 27 holders — while 29 added to existing stakes and 36 trimmed.
The largest buyer was Alpine Associates Management, opening a new position worth an estimated $93.5M. The largest seller was Wellington Management Group, cutting an estimated $179M.
- 146 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q4 2019, up from 119 in Q3 2019.
- Funds reported $2.31B of Ra Pharmaceuticals, Inc. Common Stock stock for Q4 2019, up 102% quarter-over-quarter.
- 71 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 44 closed out, a net change of +27 holders.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q4 2019 was Alpine Associates Management, an estimated $93.5M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Wellington Management Group, an estimated $179M sold.
Based on aggregated 13F filings for Q4 2019.